Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Takako Iwachido"'
Publikováno v:
Journal of Pharmacological Sciences, Vol 115, Iss 1, Pp 69-74 (2011)
We investigated the inhibitory effects of β1- or β2-adrenoceptor (AR) antagonists on salivary amylase secretion produced by various emetic agents, such as cisplatin, apomorphine, and lithium chloride (LiCl), or the non-emetic agent β1/2-AR agonist
Externí odkaz:
https://doaj.org/article/3b0b10ef514d454da491415e334354d1
Publikováno v:
Journal of Pharmacological Sciences, Vol 113, Iss 2, Pp 143-152 (2010)
We investigated the effects of various emetic agents: cisplatin, apomorphine, lithium chloride (LiCl), rolipram, sibutramine, and the β3-adrenoceptor (AR) agonist CL316243 on salivary amylase secretion in rats. We also determined the inhibitory effe
Externí odkaz:
https://doaj.org/article/95f1eda6a65e4e0bb89def468e6beede
Autor:
Hirofumi Minomo, Yoshimi Inoue, Takako Iwachido, Hiromi Oota, Koji Otabe, Katsuo Kubono, Satoshi Kondo, Daisuke Sasaki, Yusuke Suzuki, Yuta Nakamura, Hitoshi Naraoka, Masumi Higashiyama, Nozomi Fujisawa, Kumi Honda, Tadao Matsumoto, Hideki Yasui, Yoshiro Saito, Naoto Toyota
Publikováno v:
Bioanalysis. 14:1337-1348
In new drug development, cells or animals are treated with the selected candidate compound to confirm its efficacy and safety in nonclinical studies. Clinical laboratory tests are carried out using samples from experimental animals in these studies.
Publikováno v:
Journal of Pharmacological Sciences, Vol 115, Iss 1, Pp 69-74 (2011)
We investigated the inhibitory effects of β1- or β2-adrenoceptor (AR) antagonists on salivary amylase secretion produced by various emetic agents, such as cisplatin, apomorphine, and lithium chloride (LiCl), or the non-emetic agent β1/2-AR agonist
Publikováno v:
Journal of pharmacological sciences. 115(1)
We investigated the inhibitory effects of β₁- or β₂-adrenoceptor (AR) antagonists on salivary amylase secretion produced by various emetic agents, such as cisplatin, apomorphine, and lithium chloride (LiCl), or the non-emetic agent β(½)-AR ag